Medtide Inc. (03880) Sets 30 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal

Bulletin Express

03/16

Medtide Inc. (Stock Code: 03880) has scheduled a board meeting for Monday, 30 March 2026. According to the announcement released on 16 March 2026, the agenda includes:

• Reviewing and approving the consolidated annual results for the year ended 31 December 2025.

• Considering a recommendation on the payment of a final dividend, if any.

• Addressing other routine corporate matters.

Dr. Xu Qi, Chairwoman and Chief Executive Officer, signed the notice on behalf of the board.

Board composition as at the date of the announcement: – Executive Directors: Dr. Xu Qi, Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao, and Ms. Li Lingmei. – Non-executive Director: Mr. Wu Yihui. – Independent Non-executive Directors: Dr. Yu Cheung Hoi, Dr. Zhu Xun, and Mr. Xia Xinsheng.

The company emphasised that the annual results announcement and any dividend decisions will be published following board approval on 30 March 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1153266924"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153266924\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153266924?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153266924","market":"hk","top_or_hot":-1,"title":"Medtide Inc. (03880) Sets 30 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal","media":"Bulletin Express","content":"<p>Medtide Inc. (Stock Code: 03880) has scheduled a board meeting for Monday, 30 March 2026. According to the announcement released on 16 March 2026, the agenda includes:</p>\n<p>• Reviewing and approving the consolidated annual results for the year ended 31 December 2025.</p>\n<p>• Considering a recommendation on the payment of a final dividend, if any.</p>\n<p>• Addressing other routine corporate matters.</p>\n<p>Dr. Xu Qi, Chairwoman and Chief Executive Officer, signed the notice on behalf of the board.</p>\n<p>Board composition as at the date of the announcement:  \n– Executive Directors: Dr. Xu Qi, Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao, and Ms. Li Lingmei.  \n– Non-executive Director: Mr. Wu Yihui.  \n– Independent Non-executive Directors: Dr. Yu Cheung Hoi, Dr. Zhu Xun, and Mr. Xia Xinsheng.</p>\n<p>The company emphasised that the annual results announcement and any dividend decisions will be published following board approval on 30 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medtide Inc. (03880) Sets 30 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedtide Inc. (03880) Sets 30 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-16 23:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Medtide Inc. (Stock Code: 03880) has scheduled a board meeting for Monday, 30 March 2026. According to the announcement released on 16 March 2026, the agenda includes:</p>\n<p>• Reviewing and approving the consolidated annual results for the year ended 31 December 2025.</p>\n<p>• Considering a recommendation on the payment of a final dividend, if any.</p>\n<p>• Addressing other routine corporate matters.</p>\n<p>Dr. Xu Qi, Chairwoman and Chief Executive Officer, signed the notice on behalf of the board.</p>\n<p>Board composition as at the date of the announcement:  \n– Executive Directors: Dr. Xu Qi, Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao, and Ms. Li Lingmei.  \n– Non-executive Director: Mr. Wu Yihui.  \n– Independent Non-executive Directors: Dr. Yu Cheung Hoi, Dr. Zhu Xun, and Mr. Xia Xinsheng.</p>\n<p>The company emphasised that the annual results announcement and any dividend decisions will be published following board approval on 30 March 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03880","symbol_name":"泰德醫藥","start_time":0,"source_url":"","article_id":"1153266924","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153266924","pubTimestamp":1773673303,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Medtide Inc. (Stock Code: 03880) has scheduled a board meeting for Monday, 30 March 2026. According to the announcement released on 16 March 2026, the agenda includes: • Reviewing and approving the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03880":"泰德医药"},"translate_title":"Medtide Inc.(03880)定于2026年3月30日召开董事会批准2025财年业绩和股息提案","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03880":1},"content_text":"Medtide Inc. (Stock Code: 03880) has scheduled a board meeting for Monday, 30 March 2026. According to the announcement released on 16 March 2026, the agenda includes:\n• Reviewing and approving the consolidated annual results for the year ended 31 December 2025.\n• Considering a recommendation on the payment of a final dividend, if any.\n• Addressing other routine corporate matters.\nDr. Xu Qi, Chairwoman and Chief Executive Officer, signed the notice on behalf of the board.\nBoard composition as at the date of the announcement:  \n– Executive Directors: Dr. Xu Qi, Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao, and Ms. Li Lingmei.  \n– Non-executive Director: Mr. Wu Yihui.  \n– Independent Non-executive Directors: Dr. Yu Cheung Hoi, Dr. Zhu Xun, and Mr. Xia Xinsheng.\nThe company emphasised that the annual results announcement and any dividend decisions will be published following board approval on 30 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}